Non-Small Cell Lung Cancer Therapeutics Market will be valued at 10.9 billion in 2021 - PowerPoint PPT Presentation

Loading...

PPT – Non-Small Cell Lung Cancer Therapeutics Market will be valued at 10.9 billion in 2021 PowerPoint presentation | free to download - id: 804046-NzI4Z



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Non-Small Cell Lung Cancer Therapeutics Market will be valued at 10.9 billion in 2021

Description:

Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. – PowerPoint PPT presentation

Number of Views:4

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Non-Small Cell Lung Cancer Therapeutics Market will be valued at 10.9 billion in 2021


1
Non-Small Cell Lung Cancer Therapeutics in Major
Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates
A Competitive Second-Line
Published on 01 September, 2015 Number of
pages 113 Single User Price 4995
The NSCLC market will be valued at 10.9 billion
in 2021, growing from 6.1 billion in 2014 at a
CAGR of 8.5 .
2
Summary of the ReportNon-Small Cell Lung
Cancer (NSCLC) is the second most common cancer
globally, and the most common cause of
cancer-related mortality. Such a poor outlook,
particularly for patients with advanced disease,
has created a pressing need for improved
therapeutic options. The NSCLC market is
undergoing a gradual change from a focus on
generic chemotherapy regimens to complex
treatment landscape based on different NSCLC
subtypes and the presence of various molecular
aberrations. In the current market, patients
with non-squamous histology can be treated with
more efficacious therapies such as Alimta
(pemetrexed), while patients harboring activating
mutations in EGFR or ALK can be prescribed
targeted therapy. While the NSCLC developmental
pipeline must aim to improve the outlook for all
patients, there is currently a lack of options
for patients with squamous cell histology or
other detectable molecular characteristics
besides EFGR and ALK mutations.
Click Here To Check Complete Report
3
  • Scope of the Report
  • The NSCLC market will be valued at 10.9 billion
    in 2021, growing from 6.1 billion in 2014 at a
    CAGR of 8.5 -
  • How will immunotherapies such as Keytruda affect
    growth?
  • What effect will patent expirations of Tarceva
    and Alimta have on market value?
  • The NSCLC pipeline is large and diverse, with an
    increased presence of mAbs and specific targeted
    therapies in contrast to the market -
  • What are the common targets and mechanisms of
    action of pipeline therapies?
  • Will the pipeline address unmet needs such as a
    lack of treatments for squamous cell patients?
  • What implications will the increased focus on
    targeted therapies have on the future of NSCLC
    treatment?
  • Numerous late-stage pipeline therapies with a
    strong clinical record have the potential to
    enter the market over the forecast period -
  • How have promising late-stage therapies performed
    in clinical trials?
  • How would the approval of Rociletinib affect the
    competitive landscape?
  • What is the individual commercial forecast for
    each therapy?

Download Sample Brochure
4
  • Reasons to buy
  • This report will allow you to -
  • Understand the current clinical and commercial
    landscape by considering disease pathogenesis,
    diagnosis, prognosis, and the treatment options
    available at each stage of diagnosis, including a
    clinical comparison of marketed therapies.
  • Visualize the composition of the NSCLC market in
    terms of dominant therapies for each patient
    subset along with their clinical and commercial
    standing. Unmet needs in the current market are
    highlighted to allow a competitive understanding
    of gaps in the current market.
  • Analyze the NSCLC pipeline and stratify pipeline
    therapies by stage of development, molecule type
    and molecular target.
  • Understand the potential of late-stage therapies
    with extensive profiles of products that could
    enter the market over the forecast, highlighting
    clinical performance, potential commercial
    positioning, and how they will compete with other
    therapies.
  • Predict NSCLC market growth in eight major
    markets with epidemiological and ACoT forecasts
    across the US, Canada, UK, France, Germany,
    Italy, Spain and Japan, as well as individual
    drug contributions to market growth.

Make an Inquiry Before Buying
5
Non-Small Cell Lung Cancer Therapeutics in Major
Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates
A Competitive Second-Line
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Non-Small Cell Lung Cancer(NSCLC)
Therapeutics Market are provided in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Non-Small Cell Lung
Cancer(NSCLC) Therapeutics Market Report
About PowerShow.com